Both Markets Will Be Driven by New High-Priced Biologics from Savient Pharmaceuticals, Novartis and Regeneron, According to a New Report from Decision Resources
December 9, 2010 – Burlington, Mass.—Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that by 2019 the acute gout drug market will triple in size to $117 million and the chronic gout drug market will reach $1.83 billion.
According to the new report entitled Acute and Chronic Gout – New Agents Target Refractory Patients and Tap Market Opportunity, both markets will be driven by new high-priced biologics. In September 2010, Savient Pharmaceuticals’ Krystexxa became the newest approved drug for chronic gout. Novartis’s Ilaris and Regeneron’s Arcalyst are both still in development for acute gout.
“These high-priced agents will be reserved for small segments of the population. Krystexxa will be used predominantly in patients with severe treatment-refractory chronic gout, while Ilaris and Arcalyst will likely be used adjunctively with uricase-lowering treatment for patients who experience severe and frequent acute attacks,” said Matthew Scutcher, Ph.D., analyst at Decision Resources. “Nonetheless, these agents are likely to provide healthy returns for the companies involved and will drive significant market growth, largely because of their high prices.”
About Acute and Chronic Gout – New Agents Target Refractory Patients and Tap Market Opportunity
This new special report from the Spectrum series includes primary research in the form of interviews with primary care physicians/general practitioners and specialists treating gout from across the major markets. Decision Resources’ epidemiology analysis and forecasts of diagnosed chronic gout prevalence and the number of acute flares of gout over 2009-2019 are also included in the report.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.